A prospective study of MMR/MSI status detection in gastric cancer based on deep learning artificial intelligence diagnosis versus immunohistochemistry

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500107637

Enrollment

Unknown

Registered

2025-08-15

Start date

2025-08-15

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Gold Standard:Definite MMR/MSI status by immunohistochemistry testing.

Index test:MSH2,MSH6,MLH1,PMS2

Eligibility

Sex/Gender

All

Age

No minimum to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:(1) Patients with primary gastric cancer(2) No preoperative treatment: including radiotherapy, chemotherapy, immunotherapy, etc.(3) H&E pathological sections sourced from surgical resection and/or biopsy of gastric cancer pathological specimens(4) Clear MMR/MSI status confirmed through immunohistochemical testing.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: (1) The pathological section shows significant folds. (2) The pathological section is poorly scanned or not accurately focused. (3) The clinical pathological data of the patient is incomplete.

Design outcomes

Primary

Measure	Time frame
AUC;Accuracy;Sensitivity;Specificity;	—

Countries

China

Contacts

Public ContactXinke Zhang; Muyan Cai

Sun Yat-sen University Cancer Center

zhangxk@sysucc.org.cn+86 138 2609 4643

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026